The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Gains Access to Brain Cells

Back to News Homepage

Next

Anemia and Hepatitis C Treatment

Bristol-Myers Gains Momentum with All-Oral Hep C Therapy

Print this page

In a recent study, over one third of previous non-responders cleared Hepatitis C with an interferon-free combo of two Bristol-Myers experimental drugs.

Bristol-Myers Hepatitis C Pills Clear Virus Without Injections

By Drew Armstrong and Robert Langreth

Jan. 19 (Bloomberg) — Combining two experimental Bristol- Myers Squibb Co. pills cleared the hepatitis C virus in 36 percent of patients not helped by a standard treatment, in a small study testing a new approach against the liver disease.

The study is the first to suggest that difficult hepatitis C cases may be cured without using the injected drug interferon, said Anna Lok, the lead study author and director of hepatology at the University of Michigan in Ann Arbor. Interferon, a mainstay of existing treatment, causes unpleasant side effects including fatigue and flu-like symptoms.

Drug companies including Bristol-Myers, Merck & Co., Gilead Sciences Inc., and Vertex Pharmaceuticals Inc. are racing to come up with interferon-free treatment. The new results in 21 patients show that such a therapy will be possible, Lok said.

Continue reading this entire article:

http://www.businessweek.com/news/2012-01-23/bristol-myers-hepatitis-c-pills-clear-virus-without-injections.html

No Comments - be the first!
Share
Share

Previous

Hepatitis C Gains Access to Brain Cells

Back to News Homepage

Next

Anemia and Hepatitis C Treatment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.